Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @OncoAlert
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @OncoAlert
-
Prikvačeni tweet
OncoAlert 360
is a network of oncology professionals w/1 mission: Fight cancer through social media by disseminating potentially Practice Changing knowledge(#radiotherapy#chemotherapy#Immunotherapy#surgery#advocacy#cancerprevention Oncology 360 degrees)YOU are@OncoAlert
pic.twitter.com/Vvi2kFNBcZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
MONALEESA3 update: —> Ribociclib prolongs OS when added to Fulvestrant in postmenopausal women with HR+ mBC (58% vs 46% alive at 42 mo, HR 0.72, p 0.004) Of note, pts reviving fulv+ribo as 1st line achieved a mPFS OF 33 months!
@OncoAlerthttps://www.nejm.org/doi/full/10.1056/NEJMoa1911149 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
@sitcancer PD-1 Resistance Taskforce created definitions for primary resistance & 2ndary resistance. (Caveats: e.g. should not be applied to pts who discontinued early due to irAEs!). These criteria are CRITICAL as we increasingly study PD-1 resistance!#ImmunoOnc20@OncoAlertpic.twitter.com/hzLGqjnk7y
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
Effectiveness of sacubitril–valsartan in cancer
with heart failure
SAC/VAL
echocardiographic functional and structural parameters, 
NT-proBNP levels

symptomatic status in this special oncologic population
also well tolerated in these patients @secardiologiapic.twitter.com/OeQ3KTokbm
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
We are already at
@ASCO#ImmunoOnc20 Symposium, with the expert Robert Dreider, member of the Scientific Committee#oncology#Immunotherapy#oncoalertpic.twitter.com/5tBqYet5RR
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
#TDT#Neoadjuvant#Immunotherapy#anti–PD-(L)1 More than 100 clinical trials of neoadjuvant anti–PD-(L)1 therapy are currently ongoing, both as monotherapy and in combinations with other immunotherapies, radiation therapy, chemotherapy#OncoAlert https://science.sciencemag.org/content/367/6477/eaax0182 …pic.twitter.com/qvpSDmfrnh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
NEW Review by Ton N Schumacher et al, on
#CD8T cell states that have been identified in human tumours using#singlecell#RNAseq, the potential roles they play in tumour control as well as how they are influenced by#ImmuneCheckpointBlockade. http://bit.ly/CD8T_TNS@NatResCancerpic.twitter.com/inPH94vZI3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
Thrilled to see our review on Sarcomatoid/Rhabdoid RCC for
@ASCO#DailyNews published! With mentor extraordinaire@DrChoueiri. Exciting new data are emerging for this aggressive disease and our review tries to summarize it all.https://dailynews.ascopubs.org/do/10.1200/ADN.20.200037/full/ …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
I will never ever stop repeating how important is having a good work-life balance to my colleagues
@DralexGva and to traineeshttps://mindbodymiko.com/the-ugly-side-of-becoming-a-surgeon/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
@myESMO@OncoAlert a smart idea of smart young oncologists on oncotwitting!https://twitter.com/apassaromd/status/1225434607455215618 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
PIK3CA-mutated Metastatic
#BreastCancer: Analysis from SAFIR02 trial results in better understanding of characteristics of MBC population harbouring PIK3CA mutations http://ow.ly/diRX50yf2ef#bcsm@Annals_Oncology@FAndreMDpic.twitter.com/PI4YGR7KP9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
ESMO members: last few days to book your accommodation for
#ESMO20
From 10 February, the hotel booking tool will be open to all Congress participants – make the most of this member-only access now to reserve. http://ow.ly/i8OV50y7YDl pic.twitter.com/LFBQkTrHHF
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
Editorial: The return on investment of cancer-genome sequencing projects will come when that information can be used to tailor therapy to individual patients. And for that to be achieved, clinical background information on study participants is essential.https://go.nature.com/382OGuU
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
Study with
@APassaroMD@matteolambe@weoncologists@curijoey@darioT_ et al quantified commercial tweeting (big pharma & biotech) at a major international conference (#ESMO18). We excluded these tweets to study content of scientific & clinical interest. https://esmoopen.bmj.com/content/5/1/e000598.full?ijkey=Ute5KMvHrA97zOo&keytype=ref …pic.twitter.com/Bas0LCJY1P
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
An
@AliceParkNY profile on Jim Allison in@TIME Delish!https://time.com/5778987/james-allison-immunologist/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
Next at
#ImmunoOnc20 Dr. Luis Ruffolo (great to see a surgical resident on the podium!): semaphorin 4D to sensitize pancreatic cancer to checkpoint blockade. Don't want to post his unpublished data- summary: combinations with SEMA4Di+ICI increases TIL and decrease tumor growth.pic.twitter.com/4C6jaykXM7
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
Proud to announce with co-chair
@HHammersMD the 2nd Annual Kidney Cancer Research Summit,#KCRS20, a meeting focused on translational science in RCC fueled by the@CDMRP KCRP grant funding. LINK TO REGISTER/More: http://events.r20.constantcontact.com/register/event?oeidk=a07egv2jc2m65b70767&llr=id7tej8ab … please Re-tweet!pic.twitter.com/W59Z4y5whZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
Really important topic for tonight's
@lcsmchat - stigma and nihilism - join if you can#lcsm#oncoalerthttps://twitter.com/lcsmchat/status/1225232906232070145 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
Interesting paper on a hot topic. Kudos to all the authors
#oncoalerthttps://twitter.com/apassaromd/status/1225434607455215618 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
Experiences of BRCA1/2 Gene Mutation–Positive Women With Can... : Cancer Nursing
#OncoAlert - congratulations to @memnun_seven https://pdfs.journals.lww.com/cancernursingonline/9000/00000/experiences_of_brca1_2_gene_mutation_positive.98983.pdf …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
OncoAlert proslijedio/la je Tweet
Very interesting GBM study in @JAMAOnc Maximal safe resection of contrast-enhancing AND non-enhancing#glioblastoma associated w/ longer survival in patients <65 yrs -IDH mutant & wild type -IDH wild type +/- MGMT methylated#btsm#OncoAlert Link: https://ja.ma/3bgn33x pic.twitter.com/Ai7Jrbq7mg
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees
We are